chrisvoncsefalvay/vaers-outcomes huggingface dataset:
somebody who is just lost somebody and is spoken with many many people onthe internet; This spontaneous case was reported by a consumer and describes the occurrence of DEATH (somebody who is just lost somebody and is spoken with many many people onthe internet) in a 2-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. Death occurred on an unknown date The cause of death was not reported. It is unknown if an autopsy was performed.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter. Patient age was reported as 2.7 years. Treatment details were not reported by the reporter. Company comment-This spontaneous case concerns a 2-year-old child of an unknown gender, with no medical history reported, who experienced the unexpected, Fatal serious (medically significant) event of death after receiving an unspecified dose of Spikevax Bivalent .222 (Original/Omicron BA.4/5) vaccine. Latency cannot be assessed since exact vaccination date and event onset date were not disclosed. Death occurred on an unknown date. The reported cause of death was unknown. It is unknown if an autopsy was performed. No further clinical information was available for review. The benefit-risk relationship of Spikevax Bivalent .222 (Original/Omicron BA.4/5) vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 2-year-old child of an unknown gender, with no medical history reported, who experienced the unexpected, Fatal serious (medically significant) event of death after receiving an unspecified dose of Spikevax Bivalent .222 (Original/Omicron BA.4/5) vaccine. Latency cannot be assessed since exact vaccination date and event onset date were not disclosed. Death occurred on an unknown date. The reported cause of death was unknown. It is unknown if an autopsy was performed. No further clinical information was available for review. The benefit-risk relationship of Spikevax Bivalent .222 (Original/Omicron BA.4/5) vaccine is not affected by this report.; Reported Cause(s) of Death: Unknown cause of death
on March 14, 2021 that evening, chills, fever. the next day, my face was completely flushed. It faded by the next day. On March 27 at 3:30 in the morning I work up with pain in my right leg , on the inner side of the leg by knee. later in the morning I notice a large bruise.  On June 11, the same thing occurred on my left leg. I took a picture of the bruise on the right hand side of my knee. On July 3rd, the pain the back of  both legs wall painful all day.
for 5 days, the arm had a red spot and itched. on days 6-7 it was gone, on days 8-10 (today) there is a red spot and is itchy
Tingling; Numbness on my tongue; Metallic taste; This is a spontaneous report from a non-contactable consumer, the patient. A 50-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO162) via an unspecified route of administration in the left arm on 26Apr2021 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism, Grave's disease and allergic to a few foods. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication taken within two weeks of vaccination was not reported. Any other vaccines received by the patient within four weeks prior to the COVID-19 vaccine was not reported. On 26Apr2021 at 10:30, the patient experienced tingling, numbness on her tongue and metallic taste. The events did not result in doctor or other healthcare professional office/clinic visit/emergency visit. Therapeutic measures were not taken as a result of events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tingling, numbness on tongue and metallic taste was resolved on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Patient experienced inflammation at injection site and fever which waxed and wained and then resolved four days after injection.  Patient began with symptoms of inflammation at injection site again the week of Feb 3, 2020.  Today, Feb 14, 202 Patient's left arm at injection site is red, swollen, sore, itchy, and warm. Injection was given over one month ago, and patient reports these symptoms have come and gone over the previous month.
I had arm soreness initially following the shot. Now 11 days post vaccine, I continue to have left bicep soreness and I have developed intermittent benign muscle fasciculations when my arm is at rest.
light headed and hard to breath, did not report until approximately 2:55 pm blood pressure 108/72, Pso2 99% - 100% heart rate 72. Skin pink warm and dry. Respirations even and unlabored.  Had patient rest and take off mask for better ventilation.  Patient called his father. Father informed of all the above. Patient feeling better, took patient home.  Father to follow up with v-safe.  Discharged at 3:15
Patient with pain in arm, also having significant axillary lymph-node edema. Patient required re-eval in emergency room. Patient given course of antibiotics to r/o cellulitis.
Moderna administered to patient in error. No treatment needed.  Patient and parent aware. 2nd dose to be scheduled per MD guidelines.
headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, the patient experienced HEADACHE (headache). At the time of the report, HEADACHE (headache) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment drugs used. Patient will refer to HCP to find out whether she can take aspirin or tylenol after the vaccine.
vomiting; nausea; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 29-Jun-2021 and was forwarded to Moderna on 29-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (vomiting) and NAUSEA (nausea) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 03621a and 047b21a) for COVID-19 immunisation.     Concurrent medical conditions included Penicillin allergy, Drug allergy (acetaminophen), Diabetic and Hypertension.   On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form once. On 18-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Apr-2021, the patient experienced VOMITING (vomiting) and NAUSEA (nausea). On 20-May-2021, VOMITING (vomiting) had resolved. At the time of the report, NAUSEA (nausea) outcome was unknown.            No treatment information was provided by the reporter.  Action taken with mRNA-1273 in response to the event was not applicable.   This case was linked to MOD-2021-162788 (Patient Link).
3/21/21 - SOB, some wheezing, and dizziness  Over the following week: local injection site pain and rash; pain in chest exacerbated by deep breaths; other musculoskeletal pain - knee pain; L ear pain; R hand/wrist forearm shooting pain; pain in R axilla (prior h/o LAD there, possibly worse after the vaccine)  - Prednisone for msk pain (increased from 3 to 6 mg - at 6 mg for a couple of days) - Flovent HFA 110 2-4 puffs/day may have helped but s/e hoarseness  4/1 to 4/2/21 Patient updated me and I recommended: Flovent Diskus instead of HFA to see if it is tolerated better (less hoarseness / dysphonia) Discussed options for pain control Ordered SARS-CoV-2 spike Ab to help provide guidance about antibody response with one dose (caveat: normal values are unknown) - she plans to get it next week  Large local reaction has resolved (was present for about one week). Today, she still has SOB and pain in her rib cage; pain between shoulder blades. She also feels somewhat fatigued. Feels better if she can take a deep breath. These symptoms wax and wane.  Better somewhat with Flovent Diskus 1 puff BID, acupuncture, pain relievers, lidocaine patches, and muscle relaxant.
10/16/2022: Patient presented to the ED with cough, unsteady when ambulating, weakness. Physical exam significant for coarse and congested breath sounds in the mid lung fields, chronically ill-appearing male who is otherwise in no acute distress. 10/31/2022: Initially admitted to the medical floor. ID consulted for COVID-19. Treated with IV abx for superimposed bacterial pneumonia. Pt required supplemental O2, but was able to be weaned to RA at some point. Pt was treated with Decadron initially. Eventually changed to solumedrol. Respiratory status worsened again. Pt attempted to be diuresed without any improvement. Renal function has worsened. Pt had some bradycardia and sinus pauses. EP consulted. Scopolamine patch and bentyl given. As HR improved, Bentyl was weaned off. Pt had completed course of abx, but restarted on Cefepime when respiratory status worsened and WBC increased. Pt continued to decline with worsening O2 needs and worsening renal function. Palliative care was involved, but pt remained full code. He was transferred to ICU for close monitoring and possible need for intubation. He did not require intubation but was BiPAP dependent. Pt needed medications to help with anxiety as he was not tolerating BiPAP well. Renal function continued to worsen. After many family updates /discussions, it has been decided to pursue comfort care. Pt will be discharged to hospice in the hospital.  Pt found to be absent of heart beat and respirations at 1610 on 10/29/22.  Submitter does not have access to any further medical records. If further information is needed, please contact Hospital
Information has been received from a nurse practitioner concerning a 19 year old female with pertinent medical history reported as unspecified, who on 02-MAY-2008 was vaccinated with the first dose of GARDASIL vaccine (yeast), 0.5 ml, (Lot # and route not specified). Concomitant therapy included hormonal contraceptives (unspecified). On 03-MAY-2008 the mother of the patient called the office and reported that her daughter's lip swelled and there were sores and bumps on her upper and lower lip and on her tongue. The patient was told to take diphenhydramine HCL (BENADRYJ for the reactions. At the time of report the patient had not recovered. No product quality complaint was involved. Additional information has been requested.
Information has been received from a licensed practical nurse concerning a female who on an unspecified date was vaccinated with the second dose of VARIVAX (Oka/Merck) (route and site not reported) which was improperly stored. No symptoms reported. the patient received either lot number 658423/11800 or lot number 659065/1358U. The nurse did not have the patient's chart and wasn't sure which one she received. Follow-up information was received from the licensed practical nurse concerning who reported that the patient was a male. On 19-Jan-2009 the patient was vaccinated with the first dose of VARIVAX (Oka/Merck) (lot number 660402/0217X) IM (site not reported). The freezer temperature got warm and the state health department recommended repeating the dose. It was unknown if there was a illness at time of vaccination. Additional information has been requested.
Patient who is off schedule / received / 1st or 2nd doses / in 2020 and due to covid are / coming / to finish / series; This case was reported by a nurse via call center representative and described the occurrence of social problem in a adult male patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (1st and 2nd dose received in 2020).   On an unknown date, the patient received the 3rd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced social problem. On an unknown date, the outcome of the social problem was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported. The patient received their 1st or 2nd doses of Twinrix in 2020 and due to covid are not coming back in to finish their series, which led to social problem. The reporter consent to follow up vis email. This case has been linked with case US2021AMR150415 and US2021AMR150416 reported by the same reporter; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR150415:Same reporter. "Some patients" who only got 1st dose. US-GLAXOSMITHKLINE-US2021AMR150416:Same reporter. "Some patients" who only got 1st and 2nd dose.
I developed a cist under my left arm, very sore and tired for about 5 days.
The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify. Follow-up information has been received from a practice manager on 18-SEP-2018. This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided. On 06-SEP-2018, the patient was vaccinated with an improperly stored dose of GARDASIL 9 (strength and route were unknown) (lot# N032956 and expiration date 13-JUL-2020) for prophylaxis (Incorrect product storage). No adverse event was reported. The excursion temperature on 08-NOV-2017, 16-NOV-2017, 23-JAN-2018, 06-JUN-2018, 03-JUL-2018 and 14-AUG-2018   was 47 degree Celsius for maximize 15 hours. The excursion temperature on 07-DEC-2017 was 50 degree Celsius for maximize 8.75 hours. The call was not because of data logger. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001957: US-009507513-1810USA001958: US-009507513-1810USA001959: US-009507513-1809USA003709.
Following the vaccination, the injection site felt a little hard to the touch, red (about 2? in diameter) and a little warm for a week. Then on day 8, the injection site felt extremely warm/hot to the touch, hard, red, and extremely itchy. The extreme itch seemed to last 6-12 hrs on day 8 post-vaccination.
Injection site immediately became raised and grew larger with skin around site slight change in color continued to grow in size for about five minutes Benadryl 50 mg given to patient told to report continued symptoms
Moderately severe reactions like high fevers; This case was reported by a physician via call center representative and described the occurrence of fever in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was recovered/resolved.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional case details were reported as follows: This case was reported by the patients friend. The age at vaccination was not applicable for this report. The patient experienced moderately severe reactions like high fevers which lasted a few days.  No further details were provided.  Caller neglected to ask whether safety has permission to follow up.  This case has been linked with case US2020000344, reported by same reporter.      Lab Comments: on an unknown date, lab test was performed
Leg that Act-Hib administered in became very swollen and red. Pt started screaming/crying after left the office. Has not eaten and has been quite inconsolable- also, per M, does not seem to recognize her.  fever 100r.
pt had swelling and inflamation in the area, 4 days later swelling still remained and injection site had a scab
I started feeling achy in my joints and muscles about two days after the shot.  On day 4,  I had insomnia and was really sore in my muscles, lower back, neck, and joints. I was also very fatigued. On day 6, I was tired but had insomnia again and was in the midst of full Fibromyalgia flare up. I couldn't work on day 7 because I was so fatigued and sore. It is now day 8 after my shot, and I am still coping with a full Fibromyalgia flare. I have been in remission with my Fibro for over a year until I took the second Covid vaccine. Today, my joints hurt, my neck and spine hurt, my knees hurt, my eyes are sore, my brain is foggy, and I am exhausted. I have been taking ibuprofen, but it just barely helps.
Tenderness and soreness at injection site, extremely tender; Redness at injection site on her upper arm, today her arm is super red; Arm where she received the injection had issues; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Arm where she received the injection had issues), VACCINATION SITE PAIN (Tenderness and soreness at injection site, extremely tender) and VACCINATION SITE ERYTHEMA (Redness at injection site on her upper arm, today her arm is super red) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION COMPLICATION (Arm where she received the injection had issues). On 11-Mar-2021, the patient experienced VACCINATION SITE PAIN (Tenderness and soreness at injection site, extremely tender) and VACCINATION SITE ERYTHEMA (Redness at injection site on her upper arm, today her arm is super red). On 04-Mar-2021, VACCINATION COMPLICATION (Arm where she received the injection had issues) had resolved. At the time of the report, VACCINATION SITE PAIN (Tenderness and soreness at injection site, extremely tender) and VACCINATION SITE ERYTHEMA (Redness at injection site on her upper arm, today her arm is super red) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       On 12-Mar-2021, her arm where she received the vaccine was super red, extremely tender. Concomitant product used was not provided by the reporter. The patient did not receive any treatment medications.
Extreme fatigue, dizziness, fever leading to not being able to function. After a week of symptoms, went to doctor
Events: Fever (100.2); chills, short of breath; fatigue, brain fog, no appetite, nausea, vomit (bile), body aches and pains. Treatment: Sleep, Tylenol,  Vitamin C, and Zinc. Time course: 14 days
On 6/25/01, the pt had a fever and a seizure X 1. Exam was normal except for fever. Dx'd with viral induced fever versus fever from MMR and febrile seizure. On 7/21/01, had non-febrile seizure.
Intussusception: presented with vomiting and lethargy on 10/26/2018; ultrasound revealed right lower quadrant intussusception with obstruction; reduced by interventional radiology with air enema
Light skin rash on left deltoid, just south and around bicep tendon; area is also hot and hard to the touch, and itchy.  About the size of a peach.
Patient reports a few days after her vaccination she lost her taste, but it has slowly came back. Patient also reports her hearing is now muffled and feels like "pressure in my ears." Patient reports hearing loss. She also has developed a cough and stated, "I've been coughing like a fool." Patient stated she also developed psoriasis after receiving the vaccination.
On 11/21/2018, client was very fussy and sluggish, then on 11/22/2018 client was covered with hives (red bumps) all over both legs, stomach and face. However there was no fever.
The patient received the vaccine in our clinic on 11/22/17 then on the drive home, he began having difficulty breathing and lethargy. He was taken to a fire station who bagged him then he was transported to Hospital where he was placed on CPAP because his blood gas returned with a PH 7.1 and an elevated PCO2 in the 90s. He received IVFs and antibiotics and was admitted to the PICU. He was eventually intubated/ventilated for 2 days. He was temporarily on IV epinephrine due to low blood pressure the day after the vaccine. He had acute kidney injury (creatinine doubled) 2 days after he received the vaccine and an elevated sodium to 166. This improved with free water. He continues to be hospitalized 7 days after vaccination due to electrolyte abnormalities but he at his baseline respiratory, cardiovascular, and mental status. The diagnoses in his hospital chart include sepsis and aspiration pneumonia but he was at his baseline health without signs of acute illness when he received the influenza vaccine.
On 12/10/01 a report was received from a nurse regarding a 48 year old female patient who experienced flu-like symptoms after receiving the Fluvirin vaccine on 11/5/01. The patient has a history of hypertension and was taking Hyzaar for it. The patient was also taking Premarin, Allegra and Flonase. Previous exposure to the suspect product is unknown. The patient received the Fluvirin vaccine on 11/5/01 IM at the left deltoid muscle. On the same night, the patient experienced fatigue. On 11/01 the patient experienced radiating pain from the left shoulder down the left arm, then flu-like symptoms of aches and pain over the body. Some time later it was difficult for the patient to raise her left arm, and the left deltoid muscle became swollen and inflamed. The patient then developed a mass (size of a tennis ball) on the bottom side of the left arm and a sensation of fluid rushing around the chest. The patient recovered from the symptoms on 11/20/01. The reporter has assessed the causality relationship as possible because of the short time span between the injection and the first symptom.